T. Rowe Price Associates
PYXS icon

T. Rowe Price Associates’s Pyxis Oncology PYXS Stock Holding History

T. Rowe Price Associates’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,220
Closed -$23K – 3131
2025
Q1 		$23K Buy
22,220
+6,500
+41% +$8.67K ﹤0.01% 2997
2024
Q4 		$25K Hold
15,720
– – ﹤0.01% 2984
2024
Q3 		$58K Hold
15,720
– – ﹤0.01% 2910
2024
Q2 		$0 Buy
+15,720
New +$66.1K ﹤0.01% 3005

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's PYXS Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Pyxis Oncology (PYXS) in Q2 2025, closing a stake of 22,220 shares — an estimated $23K sold.

T. Rowe Price Associates first reported a position in PYXS in Q2 2024 and held it in 4 quarters. The position peaked at $58K in Q3 2024. 74 funds tracked by Wall St. Rank hold PYXS as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Pyxis Oncology position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 22,220 Pyxis Oncology shares in Q2 2025, an estimated $23K.
  • T. Rowe Price Associates first reported a position in Pyxis Oncology in Q2 2024 and held it in 4 quarters.
  • T. Rowe Price Associates's Pyxis Oncology position peaked at $58K in Q3 2024.
  • 74 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.